

## **Supporting Information**

### **Synthesis, Chiral Resolution and Enantiomers Absolute Configuration of 4-Nitropropranolol and 7-Nitropropranolol**

Rosa Sparaco,<sup>1</sup> Antonia Scognamiglio,<sup>1</sup> Angela Corvino,<sup>1</sup> Giuseppe Caliendo,<sup>1</sup> Ferdinando Fiorino,<sup>1</sup> Elisa Magli,<sup>2</sup> Elisa Perissutti,<sup>1</sup> Vincenzo Santagada,<sup>1</sup> Beatrice Severino,<sup>1</sup> Paolo Luciano,<sup>1</sup> Marcello Casertano,<sup>1</sup> Anna Aiello,<sup>1</sup> Gilberto De Nucci,<sup>3,\*</sup> Francesco Frecentese<sup>1</sup>

<sup>1</sup> Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, Naples, Italy

<sup>2</sup> Department of Public Health, University of Naples Federico II, Via D. Montesano 49, Naples, Italy

<sup>3</sup> Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), São Paulo, Campinas, Brazil

#### **Content:**


Chiral analytical HPLC: stereochemical purity and LC/MS analyses for 4-nitropropranolol and 7-nitropropranolol enantiomers.....	..... pages S2-S9
Mono and bidimensional NMR spectra of 4-nitropropranolol <b>2a</b> and 7-nitropropranolol <b>2b</b> .....	..... pages S10-S15
<sup>1</sup> H-NMR, <sup>13</sup> C-NMR and HRMS spectra for bis-MPA derivatives of 4-nitropropranolol and 7-nitropropranolol.....	..... pages S16-S27

**Peak 1 - (+)-4-Nitropropranolol**

## Analysis results:

Item	Specification	Result
<b>Appearance</b>	Yellow powder	Compliant
<b>Purity</b>	LC-MS purity >95%	Compliant
<b>Enantiomeric purity</b>	HPLC 99%	Compliant


## Stereochemical purity



**Figure S1** – chiral analytical HPLC: analysis of (+)-4-nitropropranolol

<b>Sample:</b>	4-Nitropropranolol – Peak 1	<b>Flow:</b>	1 mL/min
<b>Column:</b>	5 AMY-Coat -5 $\mu$ m Phenomenex	<b>Wavelength:</b>	254/280 nm
<b>Dimension:</b>	150 x 4.6 mm	<b>Mobile Phase:</b>	N-Hexane-Isopropanol 86:14 (+0.1% DEA)

## LC-MS Analysis - Peak 1 - (+)-4-Nitropropranolol



Peak Name	Retention Time min	Area mAU*min	Relative Area %
1	1.846	0.046	0,52
2	1.923	6.63	98.6
3	2.38	0.055	0.82




## Peak 2 - (-)-4-Nitropropanol

### Analysis results:


Item	Specification	Result
<b>Appearance</b>	Yellow powder	Compliant
<b>Purity</b>	LC-MS purity >95%	Compliant
<b>Enantiomeric purity</b>	HPLC 99%	Compliant

## Stereochemical purity





<b>Sample:</b>	4-Nitropropanol – Peak 2	<b>Flow:</b>	1 mL/min
<b>Column:</b>	5 AMY-Coat -5 µm Phenomenex	<b>Wavelength:</b>	254/280 nm
<b>Dimension:</b>	150 x 4.6 mm	<b>Mobile Phase:</b>	N-Hexane-Isopropanol 86:14 (+0.1% DEA)

## LC-MS Analysis



Peak Name	Retention Time min	Area mAU*min	Relative Area %
<b>1</b>	1.927	4.36	99.4
<b>2</b>	2.323	0.02	0.58




## Peak 1 - (+)-7-Nitropropranolol

### Analysis results:

Item	Specification	Result
<b>Appearance</b>	Yellow powder	Compliant
<b>Purity</b>	LC-MS purity >95%	Compliant
<b>Enantiomeric purity</b>	HPLC 99%	Compliant


## Stereochemical purity




**Figure S3** – chiral analytical HPLC: analysis of (d)-7-nitropropranolol

<b>Sample:</b>	7-Nitropropranolol – Peak 1	<b>Flow:</b>	1 mL/min
<b>Column:</b>	5 AMY-Coat -5 µm Phenomenex	<b>Wavelength:</b>	254/280 nm
<b>Dimension:</b>	150 x 4.6 mm	<b>Mobile Phase:</b>	N-Hexane-Isopropanol 86:14 (+0.1% DEA)

## LC-MS Analysis



Peak Name	Retention Time min	Area mAU*min	Relative Area
			%
<b>1</b>	1.854	0.077	0.24
<b>2</b>	1.945	31.29	99.4
<b>3</b>	2.140	0.12	0.39




## **Peak 2 - (-)-7-Nitropropranolol**

### **Analysis results:**

Item	Specification	Result
<b>Appearance</b>	Yellow powder	Compliant
<b>Purity</b>	LC-MS purity >95%	Compliant
<b>Enantiomeric purity</b>	HPLC 99%	Compliant


# Stereochemical purity




**Figure S4** – chiral analytical HPLC: analysis of (l)-7-nitropropranolol


<b>Sample:</b>	7-Nitropropranolol – Peak 2	<b>Flow:</b>	1 mL/min
<b>Column:</b>	5 AMY-Coat -5 µm Phenomenex	<b>Wavelength:</b>	254/280 nm
<b>Dimension:</b>	150 x 4.6 mm	<b>Mobile Phase:</b>	N-Hexane-Isopropanol 86:14 (+0.1% DEA)

## LC-MS Analysis




Peak Name	Retention Time min	Area mAU*min	Relative Area %
1	1.963	10.13	100







**Figure S5** – NMR signals of 4-nitropropranolol **2a**. NMR data obtained from racemic mixture, (+)-enantiomer and (-)-enantiomer are the same.




**Figure S6 -  $^1\text{H}$ -NMR 4-Nitropropanol ( $\text{CDCl}_3$ )**




**Figure S7 -  $^{13}\text{C}$ -NMR 4-Nitropropanol ( $\text{CDCl}_3$ )**




**Figure S8 -** HSQC 4-Nitropropanol




**Figure S9 -** HMBC 4-Nitropropanol




**Figure S10** – NMR signals of 7-nitropropranolol **2b**. NMR data obtained from racemic mixture, (+)-enantiomer and (-)-enantiomer are the same.




**Figure S11 -  $^1\text{H}$ -NMR 7-Nitropropanol ( $\text{CDCl}_3$ )**




**Figure S12 -  $^{13}\text{C}$ -NMR 7-Nitropropanol ( $\text{CDCl}_3$ )**




**Figure S13 - HSQC 7-Nitropropanol**




**Figure S14 - HMBC 7-Nitropropanol**




**Figure S15** -  $^1\text{H}$ -NMR of bis-(R)-MPA-(+)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S16** –  $^{13}\text{C}$ -NMR of bis-(R)-MPA-(+)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S17 - HRMS spectrum of bis-(R)-MPA-(+)-4-NO<sub>2</sub>-propranolol**




**Figure S18 - <sup>1</sup>H-NMR of bis-(S)-MPA-(+)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S19** –  $^{13}\text{C}$ -NMR of bis-(S)-MPA-(+)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S20** - HRMS spectrum of bis-(S)-MPA-(+)-4-NO<sub>2</sub>-propranolol




**Figure S21 -  $^1\text{H}$ -NMR of bis-(R)-MPA-(+)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S22 –  $^{13}\text{C}$ -NMR of bis-(R)-MPA-(+)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S23 - HRMS spectrum of bis-(R)-MPA-(+)-7-NO<sub>2</sub>-propranolol**




**Figure S24 - <sup>1</sup>H-NMR of bis-(S)-MPA-(+)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S25 –  $^{13}\text{C}$ -NMR of bis-(S)-MPA-(+)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S26 - HRMS spectrum of bis-(S)-MPA-(+)-7-NO<sub>2</sub>-propranolol**




**Figure S27** -  $^1\text{H}$ -NMR of bis-(R)-MPA-(-)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S28** –  $^{13}\text{C}$ -NMR of bis-(R)-MPA-(-)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S29 - HRMS spectrum of bis-(R)-MPA-(-)-4-NO<sub>2</sub>-propranolol**




**Figure S30 - <sup>1</sup>H-NMR of bis-(S)-MPA-(-)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S31 –  $^{13}\text{C}$ -NMR of bis-(S)-MPA-(-)-4-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**




**Figure S32 - HRMS spectrum of bis-(S)-MPA-(-)-4-NO<sub>2</sub>-propranolol**




**Figure S33 -**  $^1\text{H}$ -NMR of bis-(R)-MPA-(-)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S34** –  $^{13}\text{C}$ -NMR of bis-(R)-MPA-(-)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)




**Figure S35 - HRMS spectrum of bis-(R)-MPA-(-)-7-NO<sub>2</sub>-propranolol**



**Figure S36 - <sup>1</sup>H-NMR of bis-(S)-MPA-(-)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**



**Figure S37 –  $^{13}\text{C}$ -NMR of bis-(S)-MPA-(-)-7-NO<sub>2</sub>-propranolol (CDCl<sub>3</sub>)**



**Figure S38 - HRMS spectrum of bis-(S)-MPA-(-)-7-NO<sub>2</sub>-propranolol**